The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials

Bill D. Gogas1,2, MD; Christos V. Bourantas1, MD, PhD; Hector M. Garcia-Garcia3, MD, MSc, PhD; Yoshinobu Onuma1, MD; Takashi Muramatsu1, MD, PhD; Vasim Farooq1, MBChB; Roberto Diletti1, MD; Robert-Jan M. van Geuns1, MD, PhD; Bernard De Bruyne4, MD, PhD; Bernard Chevalier5, MD; Leif Thuesen6, MD; Pieter C. Smits7, MD, PhD; Dariusz Dudek8, MD; Jacques Koolen9, MD, PhD; Stefan Windecker10, MD; Robert Whitbourn11, MD; Dougal McClean12, MD; Cecile Dorange13, MS

B.D. Gogas and C.V. Bourantas contributed equally to this manuscript.

Aims: To assess serially the edge vascular response (EVR) of a bioresorbable vascular scaffold (BVS) compared to a metallic everolimus-e

Sign in to read and download the full article

Login Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

absorb bioresorbable vascular scaffoldedge vascular responsexience v metallic everolimus-eluting stent

Share on Facebook Share on Twitter Share on Linkedin

Read next article

Two-year follow-up of the NEVO ResElution-I(NEVO RES-I) trial: a randomised, multicentre comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberté paclitaxel-eluting stent in de novo native coronary artery lesions